Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... July 31, 2014 Nearly 20,000 medical professionals ... Annual Meeting & Clinical Lab Expo in ... never-before-seen breakthroughs in diagnostic research and technology that will ... As of Wednesday, July 30, more than ... Meeting & Clinical Lab Expo, with more than 10,000 ...
    (Date:7/31/2014)... Hopkins have mapped the sound-processing part of the mouse ... forest and the trees in view. Their imaging technique ... activity within mice, and it enabled the team to ... each other. The results, which represent a step toward ... online July 31 the journal Neuron . , ...
    (Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
    (Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
    Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
    ... Women with Endometriosis -, PHOENIX and BRITISH ... and Medical Center, part of Catholic Healthcare,West, one ... with 42 hospitals,in Arizona, California and Nevada and ... IXS; http://www.ixsbio.com ), a drug,development company commercializing ...
    ... NORRITON, Pa., Sept. 19 Tengion Inc., a ... of,neo-organs and neo-tissues, today announced that it was ... venture capital-backed innovation and,success at the 35th Anniversary ... Sherrill Neff, Partner at Quaker BioVentures -- a,venture ...
    ... HARBIN, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... of China ("PRC"), announced today that it,has successfully ... Europeenne (CE) certification, or CE mark, which indicates ...
    Cached Biology Technology:St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership 2St. Joseph's Hospital and InNexus Biotechnology Enter Collaborative Partnership 3Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3
    (Date:8/1/2014)... IN August 1, 2014 The Journal of ... Article and Best Great Educational Material (GEM) awards, which ... Behavior (SNEB) annual conference, "Nutrition Education Impact: Local to ... 2014. These annual awards recognize the authors of ... in JNEB, as judged by members of the JNEB ...
    (Date:8/1/2014)... , Aug. 1, 2014  LiveScan Service Provider Binary Biometrics ... team. As a result, Binary Biometrics will improve its mobile service capabilities and ... Volusia County and service several new cities such as, but ... , DeLand , Deltona , ... , New Smyrna Beach , Oak Hill ...
    (Date:7/31/2014)... study of bigeye tuna movements in the northwestern Atlantic ... Pelagics Research Center at the University of Massachusetts Amherst, ... wide geographical range with pronounced north-south movements from Georges ... high-use area off Cape Hatteras southwest of Bermuda for ... approach to study one of the most important commercial ...
    Breaking Biology News(10 mins):Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3
    ... Studies has received a $42 million gift-the largest in ... Medicine (HCGM), a research center dedicated to decoding the ... The award, from the Leona M. and Harry ... paves the way to new therapies for chronic illnesses ...
    ... DIEGO , Jan. 23, 2013 Celladon ... and development of innovative treatments for cardiovascular diseases, ... Trademark Office (USPTO) issued a notice of allowance ... that cover methods for identifying compounds that modulate ...
    ... water bottles, food containers, and baby products had a ... used to make their merchandise, an organic compound called ... asthma and cancer and altered prostate and neurological development. ... restrict BPA,s use, and the public was pressuring retailers ...
    Cached Biology News:Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 2Salk Institute awarded historic $42 million grant from the Helmsley Charitable Trust 3Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 2Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office 3BPA substitute could spell trouble 2
    ... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
    Applications: Western blotting ...
    ...
    Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
    Biology Products: